Correlation Between Statera Biopharma and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Statera Biopharma and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Statera Biopharma and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Statera Biopharma and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Statera Biopharma and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Statera Biopharma with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Statera Biopharma and Acrivon Therapeutics,.

Diversification Opportunities for Statera Biopharma and Acrivon Therapeutics,

0.35

Correlation Coefficient

Statera Biopharma  Acrivon Therapeutics,

Weak diversification

The 3 months correlation between Statera and Acrivon is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Statera Biopharma and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Statera Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Statera Biopharma are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Statera Biopharma i.e., Statera Biopharma and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Statera Biopharma and Acrivon Therapeutics,

If you would invest  696.00  in Acrivon Therapeutics, Common on September 16, 2024 and sell it today you would earn a total of  10.00  from holding Acrivon Therapeutics, Common or generate 1.44% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	4.76%
Values	Daily Returns

Statera Biopharma  vs.  Acrivon Therapeutics, Common

Statera Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Statera Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Statera Biopharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Pair Trading with Statera Biopharma and Acrivon Therapeutics,

The main advantage of trading using opposite Statera Biopharma and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Statera Biopharma position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Statera Biopharma and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.